Quantcast
Last updated on April 19, 2014 at 13:20 EDT

Animal Cell Therapies Announces $1.5 million Developmental Work in Canine Orthopedic Product Line

September 29, 2012

Animal Cell Therapies, Inc., a veterinary regenerative therapies company, is announcing the commitment of $1.5 million to develop a proprietary line of canine orthopedic products called PROTECT.

SAN DIEGO, CA (PRWEB) September 28, 2012

Animal Cell Therapies, Inc., a veterinary regenerative therapies company, is announcing the commitment of $1.5 million to develop a proprietary line of canine orthopedic products called PROTECT. This specialty category of regenerative medicine products is being developed in conjunction with top researchers at leading institutions.

“This type of financial commitment demonstrates that we are dedicated to propelling innovation and providing solutions for veterinarians, pets and pet owners,” said Dr. Kathy Petrucci, Chief Medical Officer of Animal Cell Therapies.

The dedicated funds will allow Animal Cell Therapies, in partnership with leading researchers, to fully develop the PROTECT Cell Therapy product portfolio. The portfolio will include a proprietary cell processing procedure, patented materials, precise protocols and an all-inclusive operating system.    

“We believe R&D capital allocated to strategic partnerships is a necessary step towards commercialization.” said Adam Irving, Chief Executive Officer of Animal Cell Therapies.

About Animal Cell Therapies

Founded in January 2009 in San Diego, California, Animal Cell Therapies (ACT) is the manifestation of veterinarian, Dr. Kathryn Petrucci, whose vision is to improve the lives of animals through thoughtful research and development, innovation and strategic partnerships. At the Company´s California-based stem cell research and development facility, the ACT team is focused on developing and delivering revolutionary cellular treatment and services to their customers. For more information, visit http://www.actcells.com.

For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2012/9/prweb9953692.htm


Source: prweb